AstraZeneca hits 2014 Pfizer bid price, helped by Bristol's woes
- Global stocks sag as bond 'bloodbath' shows no sign of letting up
- UPDATE: Alphabet (GOOG) Tops Q3 EPS Views; Revs Strong
- Baker Hughes (BHI), General Electric (GE) in Partnership Talks, Not Merger Talks
- Cirrus Logic, Inc. (CRUS) Q2 Results and Guidance Beat Estimates
- Amazon.com (AMZN) Misses Q3 EPS by 26c, Offers Q4 Guidance
A sign is seen at an AstraZeneca site in Macclesfield, central England May 19, 2014. REUTERS/Phil Noble
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
By Ben Hirschler
LONDON (Reuters) - AstraZeneca (NYSE: AZN) shares hit a record high on Friday, breaching for the first time the 55 pounds a share level offered by Pfizer (NYSE: PFE) in 2014 during the U.S. group's abortive $100 billion attempt to buy the drugmaker.
The British firm's stock has been on a roll recently, helped by a falling pound and speculation that Switzerland's Novartis (NASDAQ: NOVN) might be next to launch a bid. However, the shares were lifted to a high of 55.05 pounds by the misfortunes of Bristol-Myers Squibb (NYSE: BMY).
The failure of Bristol's immunotherapy drug Opdivo to slow disease progression in previously untreated patients with lung cancer as hoped was seen by investors as good news for rivals Merck & Co (NYSE: MRK) and AstraZeneca.
Analysts at Leerink, Jefferies and Deutsche Bank said the negative result with Opdivo increased the potential market opportunity for AstraZeneca's keenly watched combination of durvalumab and tremelimumab.
Crucial clinical trial results with durvalumab, both on its own and in combination with tremelimumab, are due next year.
Chief Executive Pascal Soriot believes AstraZeneca can become a major player in cancer drugs that bolster the immune system. And its ability to carve out billions of dollars in potential sales hinges not only on the effectiveness of its own products but on the competitive profile of rivals.
Cancer is currently the hottest area of research across the drugs industry and some analysts believe this could make AstraZeneca a takeover target once again, with speculation turning last week to Novartis as a bidder.
(Editing by Dale Hudson)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AstraZeneca (AZN) Shares Decline After Recruitment Paused in Head and Neck Cancer Trial
- Decker’s Outdoor (DECK) October weekly 50.50 straddle priced for movement of 9.8% into Q2
- CenturyLink (CTL) Pares Gains Following Merger Rumor, Up Less Than 10%
Create E-mail Alert Related CategoriesReuters, Trader Talk
Related EntitiesDeutsche Bank, Jefferies & Co
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!